Noradrenaline Cf (Norepinephrine)

Norepinephrine, the active ingredient in Noradrenaline Cf, is an adrenergic agonist presented as an injectable solution for intravenous use. It acts as a vasopressor to raise blood pressure and support cardiac output in patients experiencing severe hypotension, shock, or cardiac arrest.

GNH USA supplies Noradrenaline Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide, ensuring quality‑assured products and reliable logistics. The company adheres to EU GMP standards and provides comprehensive regulatory support for cross‑border distribution.

Noradrenaline Cf is used as a vasopressor to manage acute circulatory failure in critical care settings. - Hypotension: restores adequate arterial pressure to maintain organ perfusion. - Cardiogenic shock: improves systemic vascular resistance and cardiac output during severe pump failure. - Cardiac arrest: provides immediate pressor support to facilitate return of spontaneous circulation.

Norepinephrine administration may be associated with a range of adverse reactions, varying from frequent to rare but serious. Common Side Effects: - Tachycardia: increased heart rate due to β1 stimulation. - Hypertension: excessive rise in blood pressure from α1 vasoconstriction. - Headache: vascular changes causing cranial discomfort. - Peripheral ischemia: reduced blood flow to extremities leading to coldness or pain. Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening rhythm disturbances. - Tissue necrosis: severe extravasation causing local tissue death. - Pulmonary edema: fluid accumulation in lungs from increased afterload.

When using Noradrenaline Cf, clinicians should observe several safety measures to minimise risks and ensure therapeutic effectiveness. - Blood pressure monitoring: adjust infusion to maintain target MAP. - Cardiac function assessment: watch for tachyarrhythmias and myocardial ischemia. - Infusion site vigilance: avoid extravasation by using a dedicated central line. - Peripheral vascular disease: use with caution as vasoconstriction may worsen ischemia. - Concomitant MAO inhibitors: consider increased pressor response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine can interact with several medications, altering its pressor effect or increasing adverse event risk. Major Interactions (Avoid): - MAO inhibitors: may cause hypertensive crisis. - β‑blockers: can blunt β1‑mediated cardiac effects. - Other vasopressors: risk of excessive vasoconstriction. Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance hypotensive episodes after norepinephrine taper. - Diuretics: can affect intravascular volume and response. - Anesthetic agents (e.g., halothane): may potentiate cardiovascular depression. - Calcium channel blockers: may modify vascular tone response.